http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-102012027681-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4975ae0fea4a024abec52546584d7cd2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1f861d7dfdde7b233339d4838364a8e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f453ee1366a8c7cdfa87d29ffe996a5 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-02 |
| filingDate | 2012-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf99872aa6c68f4340181eeebc6a30af http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08182579afdb381c9d976c6365897201 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b26ab7bf357e9169c03f3dcaa6a4b17d |
| publicationDate | 2016-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-102012027681-A2 |
| titleOfInvention | Clindamycin local release system for the treatment of ocular toxoplasmosis. |
| abstract | Clindamycin local release system for the treatment of ocular toxoplasmosis. The present invention relates to a pharmaceutical formulation for local administration of clindamycin via the intraocular route for the reduction of systemic adverse effects and disease recurrence in the treatment of ocular toxoplasmosis. Said formulation comprises a matrix system compatible with intraocular application and may contain different drugs, in particular clindamycin hydrochloride. For system compositions the poly-1,1-lactic-co-glycolic polymer is used as a polymeric matrix. |
| priorityDate | 2012-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.